Regulus Therapeutics Cash Flow Statement

Financials in millions CAD. Fiscal year is September - August.

Millions CAD. Fiscal year is Sep - Aug.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2020
Period Ending	May '25 May 31, 2025	Aug '24 Aug 31, 2024	Aug '23 Aug 31, 2023	Aug '22 Aug 31, 2022	Aug '21 Aug 31, 2021	Aug '20 Aug 31, 2020	2016 - 2020
Net Income	-0.19	-0.16	-0.15	-0.18	-0.13	-0.4	Upgrade
Other Amortization	-	-	-	-	-	0.05	Upgrade
Asset Writedown & Restructuring Costs	-	-	-	-	-	0.14	Upgrade
Other Operating Activities	-0.02	-0.02	-	0	-0.03	-	Upgrade
Change in Accounts Receivable	0.01	0	0.03	0.06	-0.07	-0.01	Upgrade
Change in Accounts Payable	0.55	0.53	-0.02	0.11	0.21	0.2	Upgrade
Change in Other Net Operating Assets	-0.39	-0.37	0.11	0	-0	-	Upgrade
Operating Cash Flow	-0.04	-0.02	-0.02	-0.01	-0.02	-0.01	Upgrade
Long-Term Debt Issued	-	-	-	-	0.06	-	Upgrade
Long-Term Debt Repaid	-	-0.04	-	-	-	-	Upgrade
Total Debt Repaid	-	-0.04	-	-	-	-	Upgrade
Net Debt Issued (Repaid)	0.04	-0.04	-	-	0.06	-	Upgrade
Financing Cash Flow	0.04	-0.04	-	-	0.06	-	Upgrade
Net Cash Flow	-0	-0.06	-0.02	-0.01	0.04	-0.01	Upgrade
Levered Free Cash Flow	-1.26	0.04	0.03	0.06	0.04	0.06	Upgrade
Unlevered Free Cash Flow	-1.26	0.04	0.03	0.06	0.04	0.06	Upgrade
Change in Net Working Capital	1.14	-0.14	-0.12	-0.17	-0.14	-0.19	Upgrade

Updated Jan 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.